Women respond better to the treatment of lymph gland cancer with antibodies than men

October 10, 2012
Women respond better to the treatment of lymph gland cancer with antibodies than men

(Medical Xpress)—Women respond much better than men to the treatment of chronic follicular lymphoma with a monoclonal antibody that targets CD20 (rituximab). These are the findings of a multi-centre, Austria-wide study by the Arbeitsgemeinschaft medikamentöse Tumortherapie (AGMT) carried out under the supervision of the University Department of Internal Medicine I and study leader Ulrich Jäger, which has now been published in the journal Haematologica. It was also discovered that the volume of lymphoma cells has an important role to play.

Says Jäger: "This means that men with a large tumour or bone marrow infiltration respond poorest to , while women without bone marrow involvement and a small tumour respond best."

Follicular lymphoma is a chronic cancer of the lymphatic glands which frequently recurs after a temporary remission, i.e. a reduction in lymph node swelling and symptoms of illness. Around 40-50 new patients a year are treated for the condition at the University Department of Internal Medicine I. primarily occurs in the lymph nodes or in the bone marrow.

Until now, it was only known that women with this condition generally have a better prognosis. "They have also fared particularly better, however, since the antibody Rituximab has been used as treatment," says the haematologist who is (currently) also the President of the European Hematology Association (EHA).

The study has shown that blood concentrations (serum concentrations) in women are around 20 per cent higher than in men over the period of treatment with Rituximab. Women achieve saturation of the blood concentration with the antibody during the fourth cycle of therapy, significantly earlier than male patients. 

"The next step must therefore be to carry out studies in which we give men this antibody more often or at a higher dose at the very start of treatment, in order to determine whether this improves the prognosis of male ," says Jäger. "We also need to look at other conditions in which antibodies are used in order to determine whether there is a similar gender-specific effect taking place." These studies are being planned.

Explore further: Watch-and-wait OK in low-tumor burden follicular lymphoma

More information: Jäger, U. et al., "Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response." Haematologica, 2012. Doi:10.3324/haematol.2011.059246

Related Stories

Watch-and-wait OK in low-tumor burden follicular lymphoma

September 26, 2012
(HealthDay)—An initial watch-and-wait strategy does not have a detrimental effect on the freedom from treatment failure (FFTF) or overall survival rate in selected patients with low-tumor burden follicular lymphoma compared ...

Autologous stem cell transplantation does not improve os in patients with follicular lymphoma

December 21, 2011
High-dose chemotherapy and autologous stem cell transplantation (HDC-ASCT), for previously untreated patients with advanced follicular lymphoma (FL) does not improve overall survival compared with conventional-dose chemotherapy ...

Researchers’ blood cancer breakthrough

August 10, 2011
Researchers at the University of Southampton have discovered clues to why many patients do not respond to a standard drug for the blood cancer lymphoma, raising hopes that more effective treatments can be designed.

Recommended for you

Researchers develop test that can diagnose two cancer types

December 12, 2017
A blood test using infrared spectroscopy can be used to diagnose two types of cancer, lymphoma and melanoma, according to a study led by Georgia State University.

Atoh1, a potential Achilles' heel of Sonic Hedgehog medulloblastoma

December 12, 2017
Medulloblastoma is the most common type of solid brain tumor in children. Current treatments offer limited success and may leave patients with severe neurological side effects, including psychiatric disorders, growth retardation ...

Cancer-causing mutation suppresses immune system around tumours

December 12, 2017
Mutations in 'Ras' genes, which drive 25% of human cancers by causing tumour cells to grow, multiply and spread, can also protect cancer cells from the immune system, finds a new study from the Francis Crick Institute and ...

Drug suppresses spread of breast cancer caused by stem-like cells

December 12, 2017
Rare stem-like tumor cells play a critical role in the spread of breast cancer, but a vulnerability in the pathway that powers them offers a strategy to target these cells using existing drugs before metastatic disease occurs, ...

MRI scans predict patients' ability to fight the spread of cancer

December 12, 2017
A simple, non-invasive procedure that can indicate how long patients with cancer that has spread to the brain might survive and whether they are likely to respond to immunotherapy has been developed by researchers in Liverpool.

A new weapon against bone metastasis? Team develops antibody to fight cancer

December 11, 2017
In the ongoing battle between cancer and modern medicine, some therapeutic agents, while effective, can bring undesirable or even dangerous side effects. "Chemo saves lives and improves survival, but it could work much better ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.